.
MergerLinks Header Logo

Announced

Completed

Bristol Myers Squibb completed the acquisition of Forbius.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Biotechnology

Acquisition

Friendly

Majority

United States

protein engineering

biotechnology company

Private

Auction

Cross Border

Private Equity

Completed

Synopsis

Edit

Bristol Myers Squibb, an American pharmaceutical company, completed the acquisition of Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Financial terms were not disclosed. "Our portfolio of highly selective TGF-beta inhibitors has shown potential across a broad range of therapeutic areas. We are proud that Bristol Myers Squibb recognizes this potential given their global leadership in oncology and unique position to translate innovative science into meaningful treatments for patients with cancer across the globe," Ilia A. Tikhomirov, Forbius President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US